Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder

摘要: The aim of the present study was to investigate effect adjunctive olanzapine in patients with obsessive-compulsive disorder (OCD) refractory paroxetine. Twenty-one unresponsive treatment paroxetine, administered for at least 12 weeks dose 60 mg/day, participated a 12-week open-label, add-on trial (10 mg/day). psychopathological state evaluated by Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and Clinical Global Impression (CGI). Three did not complete olanzapine. In 18 completers, mean Y-BOCS score decreased significantly from 27.1±4.0 baseline 20.1±3.9 final evaluation (P<.001). Seven (38.9%) were rated as responders evaluation. Steady-state plasma concentrations paroxetine modified during coadministration. drug combination generally well tolerated initial sedation weight gain most frequent unwanted effects. Our findings confirm results previous studies indicate that addition ongoing serotonin reuptake inhibitors (SRI) may be beneficial some SRI monotherapy. D 2003 Elsevier Science Inc. All rights reserved.